We use our own and third party cookies in order to inform you about our services, to ensure that we give you the best experience on our website and to know more about your navigation habits. If you accept cookies or if you continue using this site, we'll assume your consent to our use of these cookies. You can find more information and change your cookie settings in our Cookies Policy.

Neuron Bio

Neuron Bio develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas.

Its pharma division is mainly devoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer’s disease.

Its diagnostic division develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as in the case of the Alzheimer’s disease. 

Its service division develops research projects as well as consultancy services for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area. 

Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 10 patent applications (1 of them granted recently by the US Patent and Trademark Office and other 2 also recently granted by the European Union) and exclusive platforms for drug discovery and development. 

Neol Bio, a 100% subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

Due to the use of advanced molecular biology techniques, bioprocess engineering and industrial microbiology, Neol achieves economically viable bioprocesses, thus reducing the use of chemical contaminates and assessing agricultural and industrial waste.

Neuron and Neol have facilities, laboratories and cutting-edge equipment in the biotechnology field, clean rooms, rodent and zebrafish facilities, including an own pilot plant for demonstration of the developed processes.

They have a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects, in which the company has already invested over €30 million.

Neuron Bio has facilities in Granada and Madrid that are connected with university research centers and it is quoted on the Alternative Stock Market (MAB) in Spain.

Address: Granada Health Technology Park.

Avda de la Innovación nº 1, 18016 Granada (Spain)

Phone: [+34] 958 750 598; Fax: [+34] 958 750 459